head JofIMAB
Journal of IMAB - Annual Proceeding (Scientific Papers)
Publisher: Peytchinski Publishing Ltd.
ISSN: 1312-773X (Online)
Issue: 2024, vol. 30, issue1
Subject Area: Medicine
-
DOI: 10.5272/jimab.2024301.5444
Published online: 26 March 2024

Original article
J of IMAB. 2024 Jan-Mar;30(1):5444-5451
THE COVID-19 PANDEMIC IN THE PLEVEN REGION FOR A THREE-YEAR PERIOD (MARCH 2020 – MARCH 2023)
Galya GanchevaORCID logoCorresponding Autoremail, Ivaylo PakovORCID logo, Milena KarchevaORCID logo, Kalina TerzievaORCID logo,
Department of Infectious Diseases, Epidemiology, Parasitology and Tropical Medicine, Faculty of Public Health, Medical University – Pleven, Bulgaria.

ABSTRACT:
The COVID-19 pandemic had a major impact on the capacity of health systems to continue the delivery of essential health services. While health systems were being challenged by increasing demand for care of COVID-19 patients, it was critical to maintain preventive and curative services, especially for vulnerable populations.
Materials and methods: A retrospective analysis was conducted on epidemiological and demographic characteristics of the COVID-19 pandemic in the Pleven region (March 2020 – March 29 2023). Data were obtained from annual reports of the National Statistical Institute and annual epidemiological analyses of Regional Health Inspectorate–Pleven and were analyzed using statistical software (IВМ SPSS Statistics 19.0).
Results: There were 36,308 confirmed cases of COVID-19 (medical workers – 2,176 confirmed cases), with 1,895 deaths. The cases during the years were 5,646 (2020), 16,258 (2021), 15,225 (2022). The incidence of COVID-19 in the region was 2,389; 6,964, and 6,668 at 100,000 populations in 2020, 2021 and 2022, respectively. The prevalence of the disease was 93%, 98% and 94% of all registered respiratory transmitted cases (p<0.0005). There were four waves with the highest incidence (November 2020, March 2021, October 2021, and January 2022, in concordance with registered for Bulgaria). The highest mortality of COVID-19 (15% of deaths) was registered during 2021 – 456 and 368 at 100,000 population for males and females, respectively (16% and 15% of deaths, respectively; 81% – at ages 65+).
Conclusion: The global implementation of different interventions had a significant impact on slowing down the community transmission of SARS-CoV-2. Health care and resources must be focused on the vulnerable populations.

Keywords: COVID-19, incidence, mortality,

pdf - Download FULL TEXT /PDF 1562 KB/
Please cite this article as: Gancheva G, Pakov I, Karcheva M, Terzieva K. The COVID-19 pandemic in the Pleven region for a three-year period (March 2020 – March 2023). 2024 Jan-Mar;30(1):5444-5451. [Crossref - 10.5272/jimab.2024301.5444]

Corresponding AutorCorrespondence to: Galya Ivanova Gancheva, Department of Infectious Diseases, Epidemiology, Parasitology and Tropical Medicine, Faculty of Public Health, Medical University – Pleven; 1, St. Kliment Ohridski Str., 5800, Pleven, Bulgaria; E-mail: galya_gancheva@abv.bg

REFERENCES:
1. Poutanen SM, Low DE, Henry B, Finkelstein S, Rose D, Green K, et al. Identification of Severe Acute Respiratory Syndrome in Canada. N Engl J Med. 2003 May 15;348(20):1995-2005. [PubMed]
2. Zhong N. Management and Prevention of SARS in China. Philos Trans R Soc Lond B Biol Sci. 2004July 29;359 (1447):1115-1116. [PubMed]
3. Lu L, Liu Q, Du L, Jiang S. Middle East Respiratory Syndrome Coronavirus (MERS-CoV): Challenges in Identifying its Source and Controlling its Spread. Microbes Infect. 2013 Jul-Aug;15(8-9):625-9. [PubMed]
4. Wu Z, McGoogan JM. Characteristics of and Important Lessons from the Coronavirus Disease 2019 (COVID-19) Outbreak in China. JAMA. 2020 Apr 7;323(13):1239-1242. [PubMed]
5. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020 Feb 20;382(8):727-733. [PubMed]
6. Du Toit A. Outbreak of a Novel Coronavirus. Nat. Rev. Microbiol. 2020 Mar;18(3):123. [PubMed]
7. Gralinski LE, Menachery VD. Return of the Coronavirus: 2019-nCoV. Viruses. 2020 Jan 24;12(2):135. [PubMed]
8. Gorbalenya AE, Baker SC, Baric RS, de Groot RJ, Drosten C, Gulyaeva AA, et al. Severe Acute Respiratory Syndrome-Related Coronavirus: The Species and its Viruses - a Statement of the Coronavirus Study Group. Preprint from bioRxiv. 11 Feb 2020.  [Crossref]
9. WHO COVID-19 dashboard. [Internet]
10. Dandekar AA, Perlman S. Immunopathogenesis of Coronavirus Infections: Implications for SARS. Nat Rev Immunol. 2005 Dec;5(12):917-27. [PubMed]
11. Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, et al. A New Coronavirus Associated with Human Respiratory Disease in China. Nature. 2020 Mar;579(7798):265-269. [PubMed]
12. Cai X. An Insight of Comparison between COVID-19 (2019-nCoV Disease) and SARS in Pathology and Pathogenesis. OSF Preprints. 2020. [Crossref]
13. Wu C, Chen X, Cai Y, Xia Ja, Zhou X, Xu S, et al. Risk Factors Associated with Acute Respiratory Distress Syndrome and Death in Patients with Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med. 2020 Jul 1;180(7):934-943. [PubMed]
14. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical Course and Risk Factors for Mortality of Adult Inpatients with COVID-19 in Wuhan, China: a Retrospective Cohort Study. Lancet. 2020 Mar 28;395(10229):1054-1062. [PubMed]
15. Guo L, Wei D, Zhang X, Wu Y, Li Q, Zhou M, et al. Clinical Features Predicting Mortality Risk in Patients with Viral Pneumonia: the MuLBSTA Score. Front Microbiol. 2019 Dec 3;10:2752. [PubMed]
16. Li X, Geng M, Peng Y, Meng L, Lu S. Molecular Immune Pathogenesis and Diagnosis of COVID-19. J Pharm Anal. 2020 Apr;10(2):102-108. [PubMed]
17. COVID - Coronavirus Statistics. [Internet]
18. Ettaboina SK, Nakkala K, Laddha KS. A Mini Review on SARS-COVID-19-2 Omicron Variant (B.1.1.529). Sci Med J. 2021 Dec;3(4):399-406. [Crossref]
19. Chan JF, Yuan S, Kok KH, To KK, Chu H, Yang J, et al. A Familial Cluster of Pneumonia Associated with the 2019 Novel Coronavirus Indicating Person-To-Person Transmission: a Study of a Family Cluster. Lancet. 2020 Feb 15;395(10223):514-523. [PubMed]
20. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020 Apr 30;382(18):1708-1720. [PubMed]
21. Jiang F, Deng L, Zhang L, Cai Y, Cheung CW, Xia Z. Review of the Clinical Characteristics of Coronavirus Disease 2019 (COVID-19). J Gen Intern Med. 2020 May;35:1545-1549. [PubMed]
22. Ye Z, Zhang Y, Wang Y, Huang Z, Song B. Chest CT Manifestations of New Coronavirus Disease 2019 (COVID-19): a Pictorial Review. Eur Radiol. 2020 Aug;30(8):4381-4389. [PubMed]
23. Peiris JS, Guan Y, Yuen K.Y. Severe Acute Respiratory Syndrome. Nat Med. 2004 Dec;10(12 Suppl):S88-S97. [PubMed]
24. Wong CK, Lam CW, Wu AK, Ip WK, Lee NL, Chan IH, et al. Plasma Inflammatory Cytokines and Chemokines in Severe Acute Respiratory Syndrome. Clin Exp Immunol. 2004 Apr;136(1):95-103. [PubMed]
25. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical Features of Patients Infected with 2019 Novel Coronavirus in Wuhan, China. Lancet. 2020 Feb 15;395(10223):497-506. [PubMed]
26. Prompetchara E, Ketloy C, Palaga T. Immune Responses in COVID-19 and Potential Vaccines: Lessons Learned from SARS and MERS Epidemic. Asian Pac J Allergy Immunol. 2020 Mar;38(1):1-9. [PubMed]
27. Mescher MF, Curtsinger JM, Agarwal P, Casey KA, Gerner M, Hammerbeck CD, et al. Signals Required for Programming Effector and Memory Development by CD8 + T Cells. Immunological Rev. 2006 Jun;211(1):81-92. [PubMed]
28. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and Clinical Characteristics of 99 Cases of 2019 Novel Coronavirus Pneumonia in Wuhan, China: a Descriptive Study. Lancet. 2020 Feb 15;395(10223):507-513. [PubMed]
29. Bai Y, Yao L, Wei T, Tian F, Jin DY, Chen L, et al. Presumed Asymptomatic Carrier Transmission of COVID-19. JAMA. 2020 Apr 14;323(14):1406-1407. [PubMed]
30. Zhu J, Yamane H, Paul WE. Differentiation of Effector CD4 T Cell Populations. Annu Rev Immunol. 2010; 28:445-89. [PubMed]
31. Abdulamir AS, Hafidh RR. The Possible Immunological Pathways for the Variable Immunopathogenesis of COVID-19 Infections Among Healthy Adults, Elderly and Children. Electron J Gen Med. 2020 May;17(4):em202. [Crossref]
32. Yao H-P, Lu X, Chen Q, Xu K, Chen Y, Cheng L, et al. Patient-derived Mutations Impact Pathogenicity of SARS-CoV-2. Cell Press J Sneak Peek. 30 Apr 2020. 57 Pages. [Crossref]
33. Chien JY, Hsueh PR, Cheng WC, Yu CJ, Yang PC. Temporal Changes in Cytokine/chemokine Profiles and Pulmonary Involvement in Severe Acute Respiratory Syndrome. Respirology. 2006 Nov;11(6);715-22. [PubMed]
34. Malkin CJ, Pugh PJ, Jones RD, Kapoor D, Channer KS, Jones TH. The Effect of Testosterone Replacement on Endogenous Inflammatory Cytokines and Lipid Profiles in Hypogonadal Men. J Clin Endocrinol Metab. 2004 Jul;89 (7):3313-8. [PubMed]
35. Vom Steeg LG, Klein SL. SeXX Matters in Infectious Disease Pathogenesis. Plos Pathog. 2016 Feb 18;12(2):e1005374. [PubMed]
36. Garanina E, Martynova E, Davidyuk Y, Kabwe E, Ivanov K, Titova A, et al. Cytokine Storm Combined with Humoral Immune Response Defect in Fatal Hemorrhagic Fever with Renal Syndrome Case, Tatarstan, Russia. Viruses. 2019 Jul 2;11(7):601. [PubMed]

Received: 07 January 2024
Published online: 26 March 2024

back to Online Journal